Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

S. G. P. Funnell (), W. E. Dowling, C. Muñoz-Fontela, P.-S. Gsell, D. E. Ingber, G. A. Hamilton, L. Delang, J. Rocha-Pereira, S. Kaptein, K. H. Dallmeier, J. Neyts, K. Rosenke, E. Wit, H. Feldmann, P. Maisonnasse, R. Grand, M. B. Frieman and C. M. Coleman
Additional contact information
S. G. P. Funnell: Public Health England
W. E. Dowling: Coalition for Epidemic Preparedness Innovations
C. Muñoz-Fontela: Bernhard Nocht Institute for Tropical Medicine
P.-S. Gsell: World Health Organisation
D. E. Ingber: Harvard University
G. A. Hamilton: Emulate Inc.
L. Delang: KU Leuven
J. Rocha-Pereira: KU Leuven
S. Kaptein: KU Leuven
K. H. Dallmeier: KU Leuven
J. Neyts: KU Leuven
K. Rosenke: National Institute of Health
E. Wit: National Institute of Health
H. Feldmann: National Institute of Health
P. Maisonnasse: Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT)
R. Grand: Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT)
M. B. Frieman: University of Maryland School of Medicine
C. M. Coleman: University of Nottingham, Queen’s Medical Centre

Nature Communications, 2020, vol. 11, issue 1, 1-4

Abstract: There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17907-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17907-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17907-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().